The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Macrophage activation and polarization
Martinez, F. O. (2008) · Frontiers in Bioscience · doi:10.2741/2692 · Cited by 3,160
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×
“Accumulating evidence indicates that several chemotherapeutic drugs are more efficient against tumors that are implanted in immunocompetent, with respect to immunodeficient, hosts.(1)”
BackgroundA New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,880
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Functional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Regulation of an ATG7 - beclin 1 Program of Autophagic Cell Death by Caspase-8
Yu, L., Alva, A., Su, H., Dutt, P., Freundt, E., Welsh, S., Baehrecke, E. H., & Lenardo, M. J. (2004) · Science · doi:10.1126/science.1096645 · Cited by 1,220
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., Thomas-Tikhonenko, A., & Thompson, C. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28833 · Cited by 1,137
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Lutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Mitotic catastrophe: a mechanism for avoiding genomic instability
Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834
Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 753
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460
Identification and manipulation of tumor associated macrophages in human cancers
Heusinkveld, M., & van der Burg, S. H. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-216 · Cited by 435
Endogenous IL-17 contributes to reduced tumor growth and metastasis
Kryczek, I., Wei, S., Szeliga, W., Vatan, L., & Zou, W. (2009) · Blood · doi:10.1182/blood-2008-09-177360 · Cited by 403
Lymphocyte depletion during treatment with intensive chemotherapy for cancer
Mackall, C., Fleisher, T., Brown, M., Magrath, I., Shad, A., Horowitz, M., Wexler, L., Adde, M., McClure, L., & Gress, R. (1994) · Blood · doi:10.1182/blood.v84.7.2221.2221 · Cited by 402
Redefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., & Kroemer, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1316 · Cited by 380
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Self-citationLiu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605465 · Cited by 356
Mantovani, A., Sica, A., Allavena, P., Garlanda, C., & Locati, M. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.02.008 · Cited by 350
Lesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Bracci, L., Moschella, F., Sestili, P., La Sorsa, V., Valentini, M., Canini, I., Baccarini, S., Maccari, S., Ramoni, C., Belardelli, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1209 · Cited by 256
Self-citationTreg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 255
Shurin, G. V., Tourkova, I. L., Kaneno, R., & Shurin, M. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900734 · Cited by 242
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2002) · PubMed · Cited by 238
The DNA Damage Response Induces IFN
Brzostek-Racine, S., Gordon, C., Van Scoy, S., & Reich, N. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100040 · Cited by 234
Ge, Y., Domschke, C., Stoiber, N., Schott, S., Heil, J., Rom, J., Blumenstein, M., Thum, J., Sohn, C., Schneeweiss, A., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1106-3 · Cited by 228
Zhang, L., Dermawan, K., Jin, M., Liu, R., Zheng, H., Xu, L., Zhang, Y., Cai, Y., Chu, Y., & Xiong, S. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.013 · Cited by 209
T helper 17 cell heterogeneity and pathogenicity in autoimmune disease
Ghoreschi, K., Laurence, A., Yang, X.-P., Hirahara, K., & O'Shea, J. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.06.007 · Cited by 206
Immunogenic cell death modalities and their impact on cancer treatment
Kepp, O., Tesniere, A., Schlemmer, F., Michaud, M., Senovilla, L., Zitvogel, L., & Kroemer, G. (2009) · Apoptosis · doi:10.1007/s10495-008-0303-9 · Cited by 204
Schiavoni, G., Mattei, F., Di Pucchio, T., Santini, S. M., Bracci, L., Belardelli, F., & Proietti, E. (2000) · Blood · doi:10.1182/blood.v95.6.2024 · Cited by 196
Self-citationFood groups and risk of squamous cell esophageal cancer in Northern Italy
Bosetti, C., Vecchia, C. L., Talamini, R., Simonato, L., Zambon, P., Negri, E., Trichopoulos, D., Λάγιου, Π., Bardini, R., & Franceschi, S. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000715)87:2<253::aid-ijc17>3.0.co;2-a · Cited by 191
Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice
Mundy-Bosse, B. L., Lesinski, G. B., Jaime-Ramirez, A. C., Benninger, K., Khan, M., Kuppusamy, P., Guenterberg, K., Kondadasula, S. V., Chaudhury, A. R., La Perle, K. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2670 · Cited by 189
Javeed, A., Ashraf, M., Riaz, A., Ghafoor, A., Afzal, S., & Mukhtar, M. M. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.08.009 · Cited by 172
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1259 · Cited by 170
Camouflage and sabotage: tumor escape from the immune system
Poschke, I., Mougiakakos, D., & Kiessling, R. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1012-8 · Cited by 169
Autophagy—A double‐edged sword in oncology
Apel, A., Zentgraf, H., Büchler, M. W., & Herr, I. (2009) · International Journal of Cancer · doi:10.1002/ijc.24500 · Cited by 164
Tanaka, H., Matsushima, H., Mizumoto, N., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1101 · Cited by 163
Proietti, E., Greco, G., Garrone, B., Baccarini, S., Mauri, C., Venditti, M., Carlei, D., & Belardelli, F. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1348 · Cited by 158
Self-citationDose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response
Chang, C.-L., Hsu, Y.-T., Wu, C.-C., Lai, Y.-Z., Wang, C., Yang, Y.-C., Wu, T.-C., & Hung, C.-F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2225 · Cited by 158
Kaneno, R., Shurin, G. V., Tourkova, I. L., & Shurin, M. R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-58 · Cited by 156
Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer
Najjar, Y. G., & Finke, J. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00049 · Cited by 149
Buhtoiarov, I. N., Sondel, P. M., Wigginton, J. M., Buhtoiarova, T. N., Yanke, E. M., Mahvi, D. A., & Rakhmilevich, A. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03357.x · Cited by 143
Li, Q., Teitz‐Tennenbaum, S., Donald, E. J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803773 · Cited by 140
Lorenzi, S., Mattei, F., Sistigu, A., Bracci, L., Spadaro, F., Sanchez, M., Spada, M., Belardelli, F., Gabriele, L., & Schiavoni, G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004163 · Cited by 134
Self-citationTanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1106 · Cited by 134
Nakahara, T., Uchi, H., Lesokhin, A. M., Avogadri, F., Rizzuto, G. A., Hirschhorn-Cymerman, D., Panageas, K. S., Merghoub, T., Wolchok, J. D., & Houghton, A. N. (2010) · Blood · doi:10.1182/blood-2009-11-251231 · Cited by 134
Farsaci, B., Higgins, J. P., & Hodge, J. W. (2011) · International Journal of Cancer · doi:10.1002/ijc.26219 · Cited by 127
Salem, M. L., Kadima, A. N., El-Naggar, S. A., Rubinstein, M. P., Chen, Y., Gillanders, W. E., & Cole, D. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211311.28739.e3 · Cited by 119
Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model
Matar, P., Rozados, V. R., Gervasoni, S. I., & Scharovsky, O. G. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-001-0237-3 · Cited by 119
Tongu, M., Harashima, N., Monma, H., Inao, T., Yamada, T., Kawauchi, H., & Harada, M. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1343-0 · Cited by 118
CD8+ Tumor-Infiltrating T Cells Are Trapped in the Tumor-Dendritic Cell Network
Boissonnas, A., Licata, F., Poupel, L., Jacquelin, S., Fetler, L., Krumeich, S., Théry, C., Amigorena, S., & Combadière, C. (2013) · Neoplasia · doi:10.1593/neo.121572 · Cited by 111
Sevko, A., Sade-Feldman, M., Kanterman, J., Michels, T., Falk, C. S., Umansky, L., Ramacher, M., Kato, M., Schadendorf, D., Baniyash, M., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.444 · Cited by 111
Radojčić, V., Bezak, K. B., Škarica, M., Pletneva, M., Yoshimura, K., Schulick, R. D., & Luznik, L. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0734-3 · Cited by 108
Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients
Nisticò, P., Capone, I., Palermo, B., Bello, D. D., Ferraresi, V., Moschella, F., Aricò, E., Valentini, M., Bracci, L., Cognetti, F., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23886 · Cited by 105
Self-citationder Most, R. G. V., Currie, A. J., Cleaver, A. L., Salmons, J., Nowak, A. K., Mahendran, S., Larma, I., Prosser, A., Robinson, B. W. S., Smyth, M. J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006982 · Cited by 101
Fine, J. H., Chen, P., Mesci, A., Allan, D., Gasser, S., Raulet, D. H., & Carlyle, J. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1316 · Cited by 101
Zielinski, C. C., Knapp, S., Mascaux, C., & Hirsch, F. R. (2013) · Annals of Oncology · doi:10.1093/annonc/mds647 · Cited by 99
Doloff, J. C., & Waxman, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3380 · Cited by 95
Peláez, B., Campillo, J. A., García‐Asenjo, J. A. L., & Subiza, J. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6608 · Cited by 93
Guerriero, J. L., Ditsworth, D., Catanzaro, J. M., Sabino, G. J., Furie, M. B., Kew, R. R., Crawford, H. C., & Zong, W. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003267 · Cited by 92
Bergmann‐Leitner, E. S., & Abrams, S. I. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s002620100229 · Cited by 91
Loeffler, M. W., Krüger, J. A., & Reisfeld, R. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0646 · Cited by 88
Moschella, F., Valentini, M., Aricò, E., Macchia, I., Sestili, P., D’Urso, M. T., Alessandri, C., Belardelli, F., & Proietti, E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4523 · Cited by 81
Self-citationDifferential effects of cytotoxic agents on hematopoietic progenitors.
Botnick, L. E., Hannon, E. C., Vigneulle, R. M., & Hellmän, S. (1981) · PubMed · Cited by 80
Kim, P. S., Armstrong, T. D., Hong, S., Wolpoe, M. E., Weiss, V. L., Manning, E. A., Huang, L., Murata, S., Sgouros, G., Emens, L. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34333 · Cited by 78
Correale, P., Botta, C., Cusi, M. G., Vecchio, M. T. D., Santi, M. M. D., Savellini, G. G., Bestoso, E., Apollinari, S., Mannucci, S., Marra, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26181 · Cited by 77
Kim, T., Kim, C.-H., Park, J., Park, S.-D., Kim, C. K., Chung, D., & Hong, Y.-K. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00292-09 · Cited by 75
Galetto, A., Buttiglieri, S., Forno, S., Moro, F., Mussa, A., & Matera, L. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200311000-00010 · Cited by 73
Ding, Z., Blazar, B. R., Mellor, A. L., Munn, D. H., & Zhou, G. (2010) · Blood · doi:10.1182/blood-2009-11-253336 · Cited by 72
Palermo, B., Bello, D. D., Sottini, A., Serana, F., Ghidini, C., Gualtieri, N., Ferraresi, V., Catricalà, C., Belardelli, F., Proietti, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1326 · Cited by 70
Self-citationSoeda, A., Morita‐Hoshi, Y., Makiyama, H., Morizane, C., Ueno, H., Ikeda, M., Okusaka, T., Yamagata, S., Takahashi, N. K., Hyodo, I., et al. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp112 · Cited by 68
Apétoh, L., Végran, F., Ladoire, S., & Ghiringhelli, F. (2011) · Current Molecular Medicine · doi:10.2174/156652411795976574 · Cited by 66
Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
Agarwala, S. S., & Case, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0141 · Cited by 65
Tsuchikawa, T., Miyamoto, M., Yamamura, Y., Shichinohe, T., Hirano, S., & Kondo, S. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1906-x · Cited by 63
Salem, M. L., Al-Khami, A. A., El-Naggar, S. A., Diaz-Montero, C. M., Chen, Y., & Cole, D. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902309 · Cited by 63
The Proteasome Inhibitor Bortezomib Sensitizes Melanoma Cells toward Adoptive CTL Attack
Seeger, J. M., Schmidt, P., Brinkmann, K., Hombach, A. A., Coutelle, O., Zigrino, P., Wagner‐Stippich, D., Mauch, C., Abken, H., Krönke, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3175 · Cited by 61
Wijayahadi, N., Haron, M. R., Stanslas, J., & Yusuf, Z. (2007) · Journal of Chemotherapy · doi:10.1179/joc.2007.19.6.716 · Cited by 60
Buttiglieri, S., Galetto, A., Forno, S., Andrea, M. D., & Matera, L. (2003) · International Journal of Cancer · doi:10.1002/ijc.11243 · Cited by 58
Khallouf, H., Märten, A., Serba, S., Teichgräber, V., Büchler, M. W., Jäger, D., & Schmidt, J. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31824b3a76 · Cited by 58
Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions
Ullrich, E., Bonmort, M., Mignot, G., Jacobs, B., Bosisio, D., Sozzani, S., Jalil, A., Louache, F., Bulanova, E., Geissman, F., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.7887 · Cited by 55
Bryniarski, K., Szczepanik, M., Ptak, M., Zemelka‐Wiącek, M., & Ptak, W. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70098-2 · Cited by 55
Park, S., Kang, S., Chen, X., Kim, E. J., Kim, J., Kim, N., Kim, J., & Jin, M. M. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.004 · Cited by 55
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Kim, Y. H., Choi, B. K., Oh, H. S., Kang, W. J., Mittler, R. S., & Kwon, B. S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0993 · Cited by 50
Chen, J., Huang, X., Huang, G., Chen, Y., Chen, L., & Song, H. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.1116 · Cited by 50
Administration of Cyclophosphamide Changes the Immune Profile of Tumor-bearing Mice
Liu, P., Jaffar, J., Hellström, I., & Hellström, K. E. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b56af4 · Cited by 50
Proietti, E., Moschella, F., Capone, I., & Belardelli, F. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.11.005 · Cited by 50
Self-citationSalem, M. L., El-Naggar, S. A., & Cole, D. J. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.11.011 · Cited by 48
Pillars Article: M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J. Immunol. 2000. 164: 6166–6173
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701141 · Cited by 48
Šefc, L., Pšenák, O., Sýkora, V., Šulc, K., & Nečas, E. (2003) · Stem Cells and Development · doi:10.1089/152581603321210136 · Cited by 39
Ferrari, S., Rovati, B., Porta, C., et al. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0365-4 · Cited by 33
Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide
Brooks-Kaiser, J. C., Bourque, L. A., & Hoskin, D. W. (1993) · Immunopharmacology · doi:10.1016/0162-3109(93)90015-i · Cited by 26
Kim, J., Jang, M. J., Lee, J.-I., Chung, Y. H., Jeong, J. H., Hung, C., & Kim, D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182328569 · Cited by 14
Cited by
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Metadata
- Authors
- Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F.
- Venue
- Cell Death & Differentiation
- Published
- 2013-06-21
- Volume
- 21
- Issue
- 1
- Pages
- 15-25
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2034751554
- Cited by
- 928
- References
- 122
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.